Condition category
Genetic Diseases
Date applied
27/09/2017
Date assigned
20/10/2017
Last edited
03/10/2017
Prospective/Retrospective
Retrospectively registered
Overall trial status
Ongoing
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
The aim of this study is to assess a brief, peer-delivered self-management intervention for patients with rare chronic diseases. Patients affected by four rare diseases are included in the study: neurofibromatosis type 1 (a genetic condition where tumours grow along the nerves), Marfan syndrome (a disorder of the body's connective tissues), primary sclerosing cholangitis (a chronic liver disease) and pulmonary arterial hypertension (high blood pressure in the arteries that go from the heart to the lungs).

Who can participate?
Patients aged over 16 with either neurofibromatosis type 1, Marfan syndrome, primary sclerosing cholangitis, or pulmonary arterial hypertension

What does the study involve?
Participants are randomly allocated to either an intervention group or a control group. The control group receives care as usual during the study and receives the intervention after the study has ended. The intervention group receives an intervention comprised of two components: a self-management manual and peer-counselling. For 6 weeks, participants complete the self-management manual at home. The first session includes a disease-specific information module. The manual follows an approach based on Acceptance and Commitment Therapy (ACT). ACT supports acceptance of negative conditions, feelings and thoughts rather than fighting against them and targets the question on how to live in line with one’s values. While working on the manual, participants are supported by weekly telephone conversations (max. 30 minutes) with a peer-counsellor who also has one of the four rare diseases named above. Participants’ acceptance of their illness is assessed before, directly after and 6 months after the intervention has ended.

What are the possible benefits and risks of participating?
Participating in the intervention may lead to improved disease management 6 months later compared to care as usual.

Where is the study run from?
University Medical Center Hamburg-Eppendorf (Germany)

When is the study starting and how long is it expected to run for?
November 2014 to October 2018

Who is funding the study?
Robert Bosch Foundation (Germany)

Who is the main contact?
1. Prof. Bernd Löwe
2. Dr Miriam Depping

Trial website

Contact information

Type

Scientific

Primary contact

Prof Bernd Löwe

ORCID ID

Contact details

University Medical Center Hamburg- Eppendorf | UKE
Institute and Outpatients Clinic for Psychosomatic Medicine and Psychotherapy
Building O25
Martinistr 52
Hamburg
20246
Germany

Type

Scientific

Additional contact

Dr Miriam Katharina Depping

ORCID ID

Contact details

University Medical Center Hamburg- Eppendorf | UKE
Institute and Outpatients Clinic for Psychosomatic Medicine and Psychotherapy
Building W37
Martinistr 52
Hamburg
20246
Germany

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

Patients for patients RCT

Study information

Scientific title

Patients for patients – qualified peer-counselling and self-management for patients with rare chronic diseases

Acronym

Study hypothesis

Primary hypothesis of the study is that participating in the intervention (consisting of self-management and peer-counselling) leads to a significantly stronger improvement in coping with the disease (indexed by acceptance) after the intervention compared to care as usual.

Ethics approval

Ethics Committee of the Hamburg Medical Council, 03/08/2017, ref: PV5088

Study design

Single-center unmasked randomized controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Home

Trial type

Quality of life

Patient information sheet

Not available in web format, please use the contact details to request a patient information sheet

Condition

Neurofibromatosis type 1, Marfan Syndrome, primary sclerosing cholangitis (PSC), pulmonary arterial hypertension (PAH)

Intervention

Study coordination is single centered, participants receive their Intervention at home and by phone and will be recruited from all over Germany. Participants are randomly assigned to either condition after providing informed consent. Unmasked random assignment to intervention or waiting-control group.

The 6-week intervention combines self-management and peer-counselling. Participants receive a self-management manual including 6 modules on the following topics: Disease-specific information, dealing with negative emotions, accepting negative thoughts and emotions, values and value-based goals. The information module is the only disease-specific module. All other chapters are generic and do not address a specific condition. Additionally to the manual, participants receive weekly telephone support by a peer counsellor (max. 30 minutes). During the phone calls the recipients of the questions are asked whether working on the current chapter worked and which difficulties arose. The recipients have the opportunity to ask questions regarding the content and process. Peer-counsellors are trained before the intervention starts. They further receive supervision provided by a medical psychotherapist in order to be sufficiently supported during their work. Peer-counsellors further receive consulting guidelines.

The control group receives care as usual during the study. As a waiting control group participants receive the intervention after the trial has ended.

Data assessment will take place before, directly after as well as six months after the intervention has ended. Assessed variables include patient global impression of change, coping mechanisms, quality of life, illness-perception, illness-related fears and illness-related cognitions, psychopathology, social support and optimism. Further, acceptance and subjective usefulness of the intervention will be assessed after the intervention.

Intervention type

Other

Phase

Drug names

Primary outcome measures

Subscale "Acceptance" of the Illness Cognition Questionaire (ICQ; Evers, Kraaimaat et al. 2001). The instrument assesses ways of cognitively evaluating the aversive character of a chronic illness on the scales helplessness, acceptance, and perceived benefits. Timepoints: pre-assessment (before the intervention), post-assessment (directly after the intervention) and follow-up assessment (6 months after the intervention)

Secondary outcome measures

1. Patient's belief about the efficacy of treatment, assessed using Patient Global Impression of Change (PGIC) at post and follow-up assessment
2. Coping mechanisms, assessed using the Health Education Impact Questionnaire (HeiQ; Schuler, Musekamp et al., 2013) at pre, post and follow-up assessment
3. Illness perceptions, assessed using the Illness Perception Questionnaire (IPQ-R; Glattacker, Bengel et al., 2009) at pre, post and follow-up assessment
4. Health-related quality of life, assessed using the 12-Item Short-Form Health Survey (SF-12; Ware, Kosinski et al., 1996) at pre, post and follow-up assessment
5. Presence and severity of symptoms of depression, assessed using the Patient Health Questionnaire 9-item depression scale (PHQ-9; Kroenke, Spitzer et al., 2001) at pre, post and follow-up assessment
6. Somatic symptom severity, assessed using Patient Health Questionnaire 15-item somatic scale (PHQ-15; Kroenke, Spitzer et al., 2002) at pre, post and follow-up assessment
7. The presence and severity of anxiety symptoms, assessed using the Patient Health Questionnaire 7-item anxiety scale (GAD-7; Löwe, Decker et al., 2008) at pre, post and follow-up assessment
8. Perceived social support, assessed using Social Support Questionnaire – Fragebogen zur sozialen Unterstützung (F-Sozu; Fydrich, Sommer et al., 2009) at pre, post and follow-up assessment

Other measures:
1. Client Sociodemographic and Service Receipt Inventory (CSSRI) – adapted version, used at pre assessment
2. Acceptance and perceived usefulness of the intervention and the specific modules, assessed using self-generated measure at post assessment
3. The perceived relationship with the peer consultant, assessed using self-generated measure at post assessment
4. Subjectively perceived goal achievement, assessed using self-generated measure at post assessment
5. The perceived quality of the peer-counselling sessions from the perspective of the peer-counsellor, assessed using self-generated measure at post assessment
6. Whether expectations of peer-counsellors regarding the intervention have been met, assessed using self-generated measure at post assessment
7. Sociodemographic variables, assessed at pre assessment
8. Helplessness and perceived benefits, assessed using the Illness Cognition Questionnaire (ICQ; Evers, Kraaimaat et al. 2001) at pre, post and follow-up assessment
9. Fear of the progression of the illness and future worries concerning the illness, assessed using Fear of Progression Questionnaire - Short-Form (PA-F-KF; Mehnert, Herschbach et al, 2006) at pre, post and follow-up assessment
10. Optimism and pessimism, assessed using LOT-R (Glaesmer, Hoyer et al., 2008) at pre, post and follow-up assessment
11. General self-efficacy, assessed using Self-efficacy Scale – Allgemeine Selbstwirksamkeitserwartung (SWE; Jerusalem & Schwarzer, 1999) at pre, post and follow-up assessment

Overall trial start date

10/11/2014

Overall trial end date

31/10/2018

Reason abandoned

Eligibility

Participant inclusion criteria

1. Diagnosis of one of four specific rare chronic conditions (Neurofibromatosis type 1, Marfan syndrome, primary sclerosing cholangitis, pulmonary arterial hypertension) given by a clinician
2. Limited functionality caused by the disease
3. Minimum age of 16 years
4. Willingness to participate in all parts of the intervention including the self-management manual, the peer counselling as well as willingness to answer to questionnaires
5. Sufficient German language skills

Participant type

Patient

Age group

Adult

Gender

Both

Target number of participants

128

Participant exclusion criteria

1. Life threatening state of health
2. Acute mental or physical burden requiring an immediate treatment
3. Acute suicidality
4. Current psychotherapeutic, psychosomatic or psychiatric treatment
5. Severe cognitive, auditory or visual impairment
6. Inability to answer study questionnaires

Recruitment start date

05/10/2017

Recruitment end date

28/02/2018

Locations

Countries of recruitment

Germany

Trial participating centre

Psychosomatic Medicine and Psychotherapy, University Medical Center Hamburg-Eppendorf
University Medical Center Hamburg- Eppendorf | UKE Institute and Outpatients Clinic for Psychosomatic Medicine and Psychotherapy Building O25 Martinistr 52
Hamburg
20246
Germany

Sponsor information

Organisation

University Medical Center Hamburg- Eppendorf | UKE

Sponsor details

Martinistr 52
Hamburg
20246
Germany

Sponsor type

University/education

Website

Funders

Funder type

Charity

Funder name

Robert Bosch Stiftung

Alternative name(s)

Robert Bosch Foundation

Funding Body Type

private sector organisation

Funding Body Subtype

other non-profit

Location

Germany

Results and Publications

Publication and dissemination plan

A study protocol is currently being prepared for submission to be published. Planned publication in a high-impact peer reviewed journal.

IPD sharing statement
The data sharing plans for the current study are unknown and will be made available at a later date.

Intention to publish date

31/10/2019

Participant level data

To be made available at a later date

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes